Duvortuxizumab

N/A

Report date: 2026/03/19 16:59:38

Base Information

Drug NameDuvortuxizumab
Drug Alias NameCD3xCD19 DART moleculeAnti-CD3/CD19 monoclonal-antibodyCD3-CD19 DART proteinMGD-011JNJ-64052781
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesFrance +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Research & Development Llc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksN/A